Articles published by Glaukos Corporation
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos Announces Participation in the Citi Healthcare Conference
February 15, 2023
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
February 01, 2023
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability
January 10, 2023
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
January 10, 2023
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 28, 2022
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos Corporation Announces Third Quarter 2022 Financial Results
November 02, 2022
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2
October 12, 2022
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos Announces FDA 510(k) Clearance of iStent infinite®
August 03, 2022
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3
July 13, 2022
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos Announces Executive Leadership Changes
February 07, 2022
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22
February 01, 2022
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
January 11, 2022
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos Announces FDA 510(k) Clearance of iPRIME™
January 06, 2022
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 29, 2021
From Glaukos Corporation
Via Business Wire
Tickers
GKOS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.